Nemonapride (CAS 75272-39-8)
See product citations (5)
QUICK LINKS
Nemonapride, as a selective antagonist of dopamine D2 receptors, plays a role in experimental neuroscience by influencing the pathways of dopamine, a key neurotransmitter involved in regulating neuronal signaling and behavior. Its action is rooted in its ability to selectively bind to these receptors, which are a type of G protein-coupled receptor found on neuron surfaces, thus preventing dopamine from attaching and activating these receptors. This blockade is significant because dopamine is in various physiological processes and behavioral expressions, including the modulation of reward, motivation, and fine motor control. By impeding dopamine′s normal receptor interaction, nemonapride alters the usual signaling cascades, potentially modifying the neurotransmission landscape. Nemonapride dissects the roles of dopamine in neural circuits and for understanding how alterations in dopamine transmission can affect biological and behavioral outcomes.
Nemonapride (CAS 75272-39-8) References
- Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. | Mihara, K., et al. 2000. Psychopharmacology (Berl). 149: 246-50. PMID: 10823405
- The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. | Suzuki, A., et al. 2000. Pharmacogenetics. 10: 335-41. PMID: 10862524
- Therapeutic spectrum of nemonapride and its relationship with plasma concentrations of the drug and prolactin. | Kondo, T., et al. 2000. J Clin Psychopharmacol. 20: 404-9. PMID: 10917400
- No relationship between--141C Ins/Del polymorphism in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. | Mihara, K., et al. 2001. Psychiatry Res. 101: 33-8. PMID: 11223117
- Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin. | Kondo, T., et al. 2002. Prog Neuropsychopharmacol Biol Psychiatry. 26: 287-91. PMID: 11817505
- Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors. | Terai, M., et al. 1983. Jpn J Pharmacol. 33: 749-55. PMID: 6138453
- Comparison of the effect of substituted benzamides on midbrain dopamine neurones after treatment of rats for 21 days. | Skarsfeldt, T. 1993. Eur J Pharmacol. 240: 269-75. PMID: 7902284
- Effects of benzamide derivatives on dopamine release from striatal slices of rats. | Yamada, S., et al. 1993. Kurume Med J. 40: 243-7. PMID: 8007633
- [3H]YM-09151-2 (nemonapride), a potent radioligand for both sigma 1 and sigma 2 receptor subtypes. | Ujike, H., et al. 1996. Neuroreport. 7: 1057-61. PMID: 8804051
- Dopamine D2 receptor dimers and receptor-blocking peptides. | Ng, GY., et al. 1996. Biochem Biophys Res Commun. 227: 200-4. PMID: 8858125
- Effects of SM-9018, a novel 5-HT2 and D2 receptor antagonist, on electrically-evoked [3H]acetylcholine release from rat striatal slices. | Ishida, K., et al. 1996. Gen Pharmacol. 27: 1203-7. PMID: 8981068
- Effects of YM-43611, a novel dopamine D2-like receptor antagonist, on immediate early gene expression in the rat forebrain. | Kurokawa, K., et al. 1997. Neuropsychopharmacology. 17: 27-33. PMID: 9194047
- 5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine. | Assié, MB., et al. 1997. Eur J Pharmacol. 334: 141-7. PMID: 9369342
- High-performance liquid chromatographic determination of nemonapride and desmethylnemonapride in human plasma using an electrochemical detection. | Nagasaki, T., et al. 1998. J Chromatogr B Biomed Sci Appl. 714: 293-8. PMID: 9766869
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Nemonapride, 10 mg | sc-204123 | 10 mg | $194.00 | |||
Nemonapride, 50 mg | sc-204123A | 50 mg | $811.00 |